Taiho Oncology Announcement
- Katrina Williams
- February 12, 2020
- No responses
On behalf of Taiho Oncology, Inc., we are pleased to inform you that a corporate press release, “Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML” has been issued 11 February 2020:
Thank you for sharing this news via your various communication channels. If you choose to share on your social channels, please consider tagging Taiho via Twitter using @TaihoOncology or LinkedIn with @TaihoOncologyInc.